Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients With Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

Next Previous
Trial Profile

Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients With Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Carcinoma; Endometrial cancer; Haemangiosarcoma; Lymphangiomyoma; Ovarian cancer; Perivascular epithelioid cell tumours; Sarcoma
  • Focus Expanded access; Therapeutic Use
  • Sponsors AADi; Aadi Bioscience; Whitehawk Therapeutics

Most Recent Events

  • 18 Mar 2025 According to Aadi Bioscience media release, the company relaunches as Whitehawk Therapeutics
  • 07 Jun 2022 Biomarker results from AMPECT and an expanded access presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 26 May 2022 According to an Aadi Bioscience media release, biomarker results from AMPECT and this expanded access program will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top